Ryvu Therapeutics SA (RVU) — Capital Reinvestment Ratio

Latest as of December 2022: 0.07x

Ryvu Therapeutics SA (RVU) has a Capital Reinvestment Ratio of 0.07x as of December 2022, meaning it reinvests 0% of its operating cash flow (zł59.92 Million) in capital expenditures (zł4.22 Million). Check how tangible is Ryvu Therapeutics SA's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.07x
Capex / Operating Cash Flow

Operating Cash Flow

zł59.92 Million
PLN

Capital Expenditures

zł4.22 Million
PLN

Data as of

Dec 2022
Most recent filing

Ryvu Therapeutics SA Capital Reinvestment Ratio (2017–2022)

This chart tracks Ryvu Therapeutics SA's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see Ryvu Therapeutics SA (RVU) cash flow conversion.

Annual Capital Reinvestment Ratio for Ryvu Therapeutics SA (2017–2022)

Year-by-year Capital Reinvestment Ratio for Ryvu Therapeutics SA from 2017 to 2022. See Ryvu Therapeutics SA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (PLN) Capital Expenditures YoY Change
2022 0.44x zł21.32 Million zł9.29 Million ▼ -77.8%
2017 1.96x zł10.98 Million zł21.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow